Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
FDF
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. Ag10 Hydrochloride
2. Ag-10 Hydrochloride
3. Alxn2060 Hydrochloride
4. Acoramidis (hydrochloride)
5. Alxn-2060 Hydrochloride
6. Vy9c88c2nv
7. Acoramidis Hydrochloride [usan]
8. 2242751-53-5
9. Benzoic Acid, 3-(3-(3,5-dimethyl-1h-pyrazol-4-yl)propoxy)-4-fluoro-, Hydrochloride (1:1)
10. Unii-vy9c88c2nv
11. Chembl4650226
12. Schembl20475239
13. Acoramidis Hydrochloride [jan]
14. Hy-109165a
15. Cs-0143619
16. 3-(3-(3-5-dimethyl-1h-pyrazol-4-yl)propoxy)-4-fluorobenzoic Acid Hydrochloride
| Molecular Weight | 328.76 g/mol |
|---|---|
| Molecular Formula | C15H18ClFN2O3 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 6 |
| Exact Mass | 328.0989983 g/mol |
| Monoisotopic Mass | 328.0989983 g/mol |
| Topological Polar Surface Area | 75.2 Ų |
| Heavy Atom Count | 22 |
| Formal Charge | 0 |
| Complexity | 356 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
NDC Package Code : 59116-5910
Start Marketing Date : 2021-12-30
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 59116-5911
Start Marketing Date : 2021-12-30
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT



FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
NDC Package Code : 59116-5911
Start Marketing Date : 2021-12-30
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 59116-5910
Start Marketing Date : 2021-12-30
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
About the Company : Biophore, founded in 2007, develops and manufactures niche and complex pharmaceutical products. With USFDA- and EU-approved API facilities, a dedicated intermediates site and an R&...
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
About the Company : Established in 2004, Metrochem API is one of the fastest-growing APIs, pellets & intermediates manufacturers. It has 6 dedicated manufacturing facilities for its 3 core product gro...
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
About the Company : Founded in 1984, DRL is well-known for its generic APIs and its track record in drug product development. It is one of the earliest pharma API manufacturers with a diverse portfoli...
About the Company : HRV Pharma is a global manufacturer, seller, and exporter of APIs, intermediates, pellets, food-grade chemicals, food additives, and food ingredients. The company provides sourcing...
About the Company : Neuland Laboratories, established in 1984 and headquartered in Hyderabad, is a publicly listed company offering solutions for pharmaceutical chemistry needs—from library compound...
About the Company : Maithri Drugs Pvt. Ltd. is a global supplier of Active Pharmaceutical Ingredients (APIs), serving pharmaceutical companies in 60+ countries. Its API portfolio spans antivirals, ant...
About the Company : Chemvisai Labs is a dynamic pharmaceutical partner established with a clear vision: to become a leading and trusted force in the industry. We address critical unmet medical needs t...

About the Company : Erythro Pharma specializes in large-scale custom chemical manufacturing for pharmaceutical, agrochemical, specialty and fine chemical sectors. The organization delivers integrated ...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Acoramidis is a Other Small Molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Amyloidosis, Hereditary, Transthyretin-Related.
Lead Product(s): Acoramidis Hydrochloride,Inapplicable
Therapeutic Area: Genetic Disease Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 11, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Acoramidis Hydrochloride,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Long-Term Safety of Acoramidis In Newly Diagnosed ATTR-CM
Details : Acoramidis is a Other Small Molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Amyloidosis, Hereditary, Transthyretin-Related.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 11, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Beyonttra (acoramidis hydrochloride) is an orally administered near-complete stabilizer of TTR for the treatment of transthyretin amyloidosis in adult patients with cardiomyopathy.
Lead Product(s): Acoramidis Hydrochloride,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Beyonttra
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: HealthCare Royalty
Deal Size: $300.0 million Upfront Cash: $300.0 million
Deal Type: Agreement June 30, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Acoramidis Hydrochloride,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : HealthCare Royalty
Deal Size : $300.0 million
Deal Type : Agreement
BridgeBio Raises $300 Million Through Partial Capped Monetization
Details : Beyonttra (acoramidis hydrochloride) is an orally administered near-complete stabilizer of TTR for the treatment of transthyretin amyloidosis in adult patients with cardiomyopathy.
Product Name : Beyonttra
Product Type : Miscellaneous
Upfront Cash : $300.0 million
June 30, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Attruby (acoramidis) is a transthyretin stabilizer being investigated for the treatment of younger patients with cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM).
Lead Product(s): Acoramidis HCl,Acoramidis Hydrochloride,Inapplicable
Therapeutic Area: Genetic Disease Brand Name: Attruby
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 13, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Acoramidis HCl,Acoramidis Hydrochloride,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
First Participant Dosed with Acoramidis in ATTR ACT-EARLY Prevention Study
Details : Attruby (acoramidis) is a transthyretin stabilizer being investigated for the treatment of younger patients with cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM).
Product Name : Attruby
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 13, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Beyonttra is an orally administered stabilizer of transthyretin (TTR) indicated for the treatment of wild-type or variant transthyretin amyloidosis in adult patients with cardiomyopathy.
Lead Product(s): Acoramidis Hydrochloride,Inapplicable
Therapeutic Area: Genetic Disease Brand Name: Beyonttra
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 28, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Acoramidis Hydrochloride,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
BEYONTTRA Approved in UK for ATTR-CM As A Near-Complete TTR Stabilizer
Details : Beyonttra is an orally administered stabilizer of transthyretin (TTR) indicated for the treatment of wild-type or variant transthyretin amyloidosis in adult patients with cardiomyopathy.
Product Name : Beyonttra
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 28, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Beyonttra (acoramidis) is a next-generation, orally-administered, highly potent, small molecule stabiliser of transthyretin. It is approved for the treatment of Transthyretin Amyloid Cardiomyopathy.
Lead Product(s): Acoramidis Hydrochloride,Inapplicable
Therapeutic Area: Genetic Disease Brand Name: Beyonttra
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 27, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Acoramidis Hydrochloride,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Beyonttra (Acoramidis) Approved in Japan as First Near-Complete TTR Stabilizer
Details : Beyonttra (acoramidis) is a next-generation, orally-administered, highly potent, small molecule stabiliser of transthyretin. It is approved for the treatment of Transthyretin Amyloid Cardiomyopathy.
Product Name : Beyonttra
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 27, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Acoramidis is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Amyloidosis.
Lead Product(s): Acoramidis Hydrochloride,Inapplicable
Therapeutic Area: Genetic Disease Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 21, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Acoramidis Hydrochloride,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Acoramidis is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Amyloidosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 21, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Acoramidis is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Cardiomyopathy-associated with Amyloidosis, Hereditary, Transthyretin-Related.
Lead Product(s): Acoramidis Hydrochloride,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 03, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Acoramidis Hydrochloride,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants
Details : Acoramidis is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Cardiomyopathy-associated with Amyloidosis, Hereditary, Transthyretin-Related.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 03, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Acoramidis is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Acoramidis Hydrochloride,Inapplicable
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Celerion
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 12, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Acoramidis Hydrochloride,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Celerion
Deal Size : Inapplicable
Deal Type : Inapplicable
Study to Assess the Effect of Food on a Single Dose of Acoramidis in Healthy Adult Participants
Details : Acoramidis is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 12, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Acoramidis is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Amyloid Neuropathies, Familial.
Lead Product(s): Acoramidis Hydrochloride,Inapplicable
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 12, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Acoramidis Hydrochloride,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Acoramidis is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Amyloid Neuropathies, Familial.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 12, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Acoramidis is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Amyloidosis.
Lead Product(s): Acoramidis Hydrochloride,Inapplicable
Therapeutic Area: Genetic Disease Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 24, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Acoramidis Hydrochloride,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Acoramidis is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Amyloidosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 24, 2021

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
28 Sep 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/09/28/3157362/0/en/Acoramidis-Begins-to-Reduce-Cumulative-Cardiovascular-Outcomes-Within-the-First-Month-of-Treatment-in-Patients-with-ATTR-CM.html

20 May 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/05/20/3084731/0/en/Acoramidis-Reduced-Incidence-of-Atrial-Fibrillation-Events-in-Patients-with-ATTR-CM.html

19 May 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/05/19/3084268/0/en/Early-and-Sustained-Increase-in-Serum-TTR-Levels-by-Acoramidis-Independently-Predicted-Improved-Survival-in-the-ATTRibute-CM-Study.html

13 May 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/05/13/3079989/0/en/First-Participant-Dosed-with-Acoramidis-in-ACT-EARLY-the-First-Ever-ATTR-Primary-Prevention-Study.html

28 Apr 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/04/28/3068975/0/en/BEYONTTRA-acoramidis-the-First-Near-complete-TTR-Stabilizer-90-Approved-by-the-UK-Medicines-and-Healthcare-Products-Regulatory-Agency-to-Treat-ATTR-CM.html

27 Aug 2023
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2023/08/27/2732246/0/en/BridgeBio-presents-detailed-positive-results-from-Phase-3-ATTRibute-CM-study-of-acoramidis-for-patients-with-transthyretin-amyloid-cardiomyopathy-ATTR-CM-at-European-Society-of-Car.html
Market Place
Patents & EXCLUSIVITIES
Patent Expiration Date : 2039-03-22
US Patent Number : 12070449
Drug Substance Claim :
Drug Product Claim :
Application Number : 216540
Patent Use Code : U-4046
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2039-03-22

Patent Expiration Date : 2039-08-16
US Patent Number : 12005043
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 216540
Patent Use Code : U-4046
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2039-08-16

Patent Expiration Date : 2031-05-05
US Patent Number : 10398681
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 216540
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2031-05-05

Patent Expiration Date : 2031-05-05
US Patent Number : 9642838
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 216540
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2031-05-05

Patent Expiration Date : 2031-05-05
US Patent Number : 9169214
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 216540
Patent Use Code : U-4046
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2031-05-05

Patent Expiration Date : 2031-05-05
US Patent Number : 8877795
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 216540
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2031-05-05

Patent Expiration Date : 2031-05-05
US Patent Number : 9913826
Drug Substance Claim :
Drug Product Claim :
Application Number : 216540
Patent Use Code : U-4046
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2031-05-05

Patent Expiration Date : 2039-03-22
US Patent Number : 11058668
Drug Substance Claim :
Drug Product Claim :
Application Number : 216540
Patent Use Code : U-4046
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2039-03-22

Patent Expiration Date : 2039-08-16
US Patent Number : 11260047
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 216540
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2039-08-16

Patent Expiration Date : 2031-05-05
US Patent Number : 10842777
Drug Substance Claim :
Drug Product Claim :
Application Number : 216540
Patent Use Code : U-4046
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2031-05-05

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Exclusivity Code : NCE
Exclusivity Expiration Date : 2029-11-22
Application Number : 216540
Product Number : 1
Exclusivity Details :

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Exclusivity Code : ODE-506
Exclusivity Expiration Date : 2031-11-22
Application Number : 216540
Product Number : 1
Exclusivity Details :

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
12
PharmaCompass offers a list of Acoramidis Hydrochloride API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Acoramidis Hydrochloride manufacturer or Acoramidis Hydrochloride supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Acoramidis Hydrochloride manufacturer or Acoramidis Hydrochloride supplier.
PharmaCompass also assists you with knowing the Acoramidis Hydrochloride API Price utilized in the formulation of products. Acoramidis Hydrochloride API Price is not always fixed or binding as the Acoramidis Hydrochloride Price is obtained through a variety of data sources. The Acoramidis Hydrochloride Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Acoramidis Hydrochloride manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Acoramidis Hydrochloride, including repackagers and relabelers. The FDA regulates Acoramidis Hydrochloride manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Acoramidis Hydrochloride API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Acoramidis Hydrochloride manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Acoramidis Hydrochloride supplier is an individual or a company that provides Acoramidis Hydrochloride active pharmaceutical ingredient (API) or Acoramidis Hydrochloride finished formulations upon request. The Acoramidis Hydrochloride suppliers may include Acoramidis Hydrochloride API manufacturers, exporters, distributors and traders.
click here to find a list of Acoramidis Hydrochloride suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Acoramidis Hydrochloride as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Acoramidis Hydrochloride API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Acoramidis Hydrochloride as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Acoramidis Hydrochloride and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Acoramidis Hydrochloride NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Acoramidis Hydrochloride suppliers with NDC on PharmaCompass.
Acoramidis Hydrochloride Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Acoramidis Hydrochloride GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Acoramidis Hydrochloride GMP manufacturer or Acoramidis Hydrochloride GMP API supplier for your needs.
A Acoramidis Hydrochloride CoA (Certificate of Analysis) is a formal document that attests to Acoramidis Hydrochloride's compliance with Acoramidis Hydrochloride specifications and serves as a tool for batch-level quality control.
Acoramidis Hydrochloride CoA mostly includes findings from lab analyses of a specific batch. For each Acoramidis Hydrochloride CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Acoramidis Hydrochloride may be tested according to a variety of international standards, such as European Pharmacopoeia (Acoramidis Hydrochloride EP), Acoramidis Hydrochloride JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Acoramidis Hydrochloride USP).